Cargando…

Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response

The introduction of a direct-acting antiviral (DAA) for patients with hepatitis C virus (HCV) infection, could lead to higher sustained virologic response (SVR) rates with fewer adverse events, and it could shorten the treatment duration relative to the interferon era. Although most recent clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasaki, Reina, Kanda, Tatsuo, Kato, Naoya, Yokosuka, Osamu, Moriyama, Mitsuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323517/ https://www.ncbi.nlm.nih.gov/pubmed/30631394 http://dx.doi.org/10.4254/wjh.v10.i12.898

Ejemplares similares

Exosomes and Hepatocellular Carcinoma: From Bench to Bedside
por: Sasaki, Reina, et al.
Publicado: (2019)

Hepatitis C Virus and Hepatocellular Carcinoma
por: Kanda, Tatsuo, et al.
Publicado: (2013)

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2018)

Superinfection of hepatitis A virus in hepatocytes infected with hepatitis B virus
por: Win, Nan Nwe, et al.
Publicado: (2019)

Follow-Up of Patients Who Achieved Sustained Virologic Response after Interferon-Free Treatment against Hepatitis C Virus: Focus on Older Patients
por: Nirei, Kazushige, et al.
Publicado: (2021)

Molecular Changes in Relation to Alcohol Consumption and Hepatocellular Carcinoma
por: Sasaki-Tanaka, Reina, et al.
Publicado: (2022)

Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes
por: Sasaki-Tanaka, Reina, et al.
Publicado: (2022)

Treatment of hepatitis C virus infection in the future
por: Kanda, Tatsuo, et al.
Publicado: (2013)

Evaluation of Potential Anti-Hepatitis A Virus 3C Protease Inhibitors Using Molecular Docking
por: Sasaki-Tanaka, Reina, et al.
Publicado: (2022)

Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Cell Culture Systems and Drug Targets for Hepatitis A Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2020)

The androgen receptor as an emerging target in hepatocellular carcinoma
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Molecular Mechanisms, Diagnosis and Treatments in Digestive Malignancy
por: Kanda, Tatsuo, et al.
Publicado: (2023)

Hepatitis A Virus Infection and Molecular Research
por: Kanda, Tatsuo, et al.
Publicado: (2022)

Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review
por: Kanda, Tatsuo, et al.
Publicado: (2019)

Masitinib Inhibits Hepatitis A Virus Replication
por: Sasaki-Tanaka, Reina, et al.
Publicado: (2023)

Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma
por: Midorikawa, Yutaka, et al.
Publicado: (2019)

Occurrence and Recurrence of Hepatocellular Carcinoma Were Not Rare Events during Phlebotomy in Older Hepatitis C Virus-Infected Patients
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Knockdown of Mitogen-Activated Protein Kinase Kinase 3 Negatively Regulates Hepatitis A Virus Replication
por: Kanda, Tatsuo, et al.
Publicado: (2021)

Effect of Previous Interferon-based Therapy on Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma
por: Saito, Tomoko, et al.
Publicado: (2014)

Faldaprevir for the Treatment of Hepatitis C
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Possible Involvement of Hepatitis B Virus Infection of Hepatocytes in the Attenuation of Apoptosis in Hepatic Stellate Cells
por: Sasaki, Reina, et al.
Publicado: (2016)

Suppressors of Cytokine Signaling and Hepatocellular Carcinoma
por: Masuzaki, Ryota, et al.
Publicado: (2022)

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma
por: Sohn, Won
Publicado: (2021)

Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature
por: Haga, Yuki, et al.
Publicado: (2017)

Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Nonzero Risk of Hepatocellular Carcinoma Even after Sustained Virological Response
por: Lee, Hyun Woong
Publicado: (2016)

Hepatitis B Virus Genotype C is Predominant in Myanmar
por: Nwe Win, Nan, et al.
Publicado: (2017)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy
por: Nakamoto, Shingo, et al.
Publicado: (2015)

Hepatitis C Virus Nonstructural Protein 5A Inhibits MG132-Induced Apoptosis of Hepatocytes in Line with NF-κB-Nuclear Translocation
por: Jiang, Xia, et al.
Publicado: (2015)

Glucose-regulated protein 78 is an antiviral against hepatitis A virus replication
por: Jiang, Xia, et al.
Publicado: (2017)

New treatments for genotype 1 chronic hepatitis C – focus on simeprevir
por: Kanda, Tatsuo, et al.
Publicado: (2014)

The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection
por: Kim, Tae Yeob
Publicado: (2012)

Hepatic STAT1-Nuclear Translocation and Interleukin 28B Polymorphisms Predict Treatment Outcomes in Hepatitis C Virus Genotype 1-Infected Patients
por: Miyamura, Tatsuo, et al.
Publicado: (2011)

Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2016)

Co-Occurrence of Hepatitis A Infection and Chronic Liver Disease
por: Kanda, Tatsuo, et al.
Publicado: (2020)

Cooperative effects of hepatitis B virus and TNF may play important roles in the activation of metabolic pathways through the activation of NF-κB
por: Wu, Shuang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5h4anphiajal320p4ae7ptmvn7